Zydus Lifesciences is poised to make a significant entry into the global biologics CDMO business through the acquisition of US-based Genus Inc. This move aligns with Zydus’ strategic vision in biologics and their commitment to developing innovative solutions for unmet medical needs, particularly in the field of immuno-oncology. The collaboration with Agenus, a key player in immuno-oncology research, combined with Zydus’ strong presence as the largest Indian oncology company, represents a major advancement in the fight against cancer. The partnership aims to deliver transformative therapies to patients in India and Sri Lanka, addressing critical healthcare needs in these markets.
Read more from financialexpress.com
